Last update 21 Nov 2024

Ori-T602

Overview

Basic Info

Drug Type
TIL therapy
Synonyms
Target-
Mechanism-
Therapeutic Areas
NeoplasmsUrogenital Diseases
Active Indication
Metastatic Carcinoma to the Uterine CervixRecurrent Cervical Cancer
Inactive Indication-
Originator Organization
OriCell Therapeutics Co.,Ltd.OriCell Therapeutics Co.,Ltd.
Active Organization
OriCell Therapeutics Co.,Ltd.OriCell Therapeutics Co.,Ltd.
Inactive Organization-
Drug Highest PhaseEarly Phase 1
First Approval Date-
Regulation-
Login to view timeline

Related

3
Clinical Trials associated with Ori-T602
CTIS2023-504632-17-00 / Not yet recruitingIIT
A phase 2, Multicenter Study of TILs Treatment in Advanced Tumors with Alterations in the SWI/SNF Complex: the TILTS Study
ChiCTR2000041256 / RecruitingEarly Phase 1IIT
An exploratory study of TILs treatment for metastatic or recurrent cervical cancer
NCT04674488 / RecruitingEarly Phase 1
An Exploratory Clinical Study of TILs Treatment for Metastatic or Recurrent Cervical Cancer
100 Clinical Results associated with Ori-T602
Login to view more data
100 Translational Medicine associated with Ori-T602
Login to view more data
100 Patents (Medical) associated with Ori-T602
Login to view more data
100 Deals associated with Ori-T602
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Carcinoma to the Uterine CervixPhase 1
CN
OriCell Therapeutics Co.,Ltd.OriCell Therapeutics Co.,Ltd.
09 Dec 2020
Recurrent Cervical CancerPhase 1
CN
OriCell Therapeutics Co.,Ltd.OriCell Therapeutics Co.,Ltd.
09 Dec 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
SITC2014
Phase 1
Glioma
NY-ESO-1 | Survivin | EGFRvIII
15
IL-2/IL-15/IL-21
jxbqbmetul(qxuiobtgvx) = dlipsazayb anrqswxert (serzodxxne, 3.40%)
View more
-
06 Nov 2014
(OKT-3 and irradiated, allogeneic feeder cells)
jxbqbmetul(qxuiobtgvx) = etoewsdhml anrqswxert (serzodxxne, 3.40%)
View more
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free